In April 2026, the FDA approved semaglutide 7.2 mg (Wegovy HD) under an accelerated review process
Whilst GLP-1 receptor agonists do not typically cause increased urination as a primary adverse effect, patients may experience urinary changes for several reasons related to their treatment journey
7: Masnec S, Kokot A, Kralj T, Zlatar M, Loncaric K, Sablic M, Kalauz M, Beslic I, Oroz K, Mrvelj B, Beketic Oreskovic L, Oreskovic I, Strbe S, Staresinic B, Slivsek G, Boban Blagaic A, Seiwerth S, Skrtic A, Sikiric P
Visible improvements from the first application
Reading about dosages online is easy